Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

ELTP RSS Feed
Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: dr_lowenstein, DR Ryan, NASDAQ2020, IB_, namtae, JustGoDeep
Search This Board: 
Last Post: 11/28/2020 1:46:31 AM - Followers: 886 - Board type: Free - Posts Today: 1

((((((  Elite Pharmaceuticals, Inc.  ))))))



Above drafted by poster Meshcan

\Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company developing a pipeline of proprietary pharmacological abuse-deterrent opioid products and niche generic products. Elite specializes in oral sustained and controlled release drug products with high barriers to entry. Elite owns generic which have been licensed to TAGI Pharma, Epic Pharma, Dr. Reddy’s Laboratories and Glenmark Pharmaceuticals Inc., USA.

Elite currently has eight commercial products currently being sold, six products filed with the FDA, additional approved products pending manufacturing site transfer and the NDA filing for SequestOx™.

Elite’s pipeline products include abuse-deterrent opioids utilizing the Company’s patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse.


Located in Northvale, New Jersey, Elite operates a 55,000 square foot campus under Current Good Manufacturing Practice (“cGMP”) and is a United States Drug Enforcement Agency (“DEA”) registered facility for research, development, manufacturing and packaging of pharmaceutical products.
 

SEEKING ALPHA ARTICLE   Jan 01, 2020 
https://seekingalpha.com/article/4314697-breaking-out-of-chrysalis-elite-transformation?utm_medium=email&utm_source=seeking_alpha?app=1#alt2

About Elite's Abuse Deterrent Technology

Elite's abuse deterrent products utilize the Company's proprietary pharmacological abuse deterrent technology. Elite's abuse deterrent technology is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist. Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers.
\
 
Elite continues to expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has four US patents, one European patent, and two Canadian patents issued in this area with additional patents pending in the U.S., Canada and Europe.

More information including Elite’s proprietary Abuse Resistant Technology can be found at http://www.elitepharma.com
 

Products & Pipeline
 
Screen%20Shot%202017-05-28%20at%2011.53.29%20AM.png
 
Elite’s principle product is SequestOx™,  an immediate-release oxycodone with sequestered naltrexone abuse-deterrent opioid product for the management of moderate to severe acute pain. Additional products include bariatric, cardiovascular, antihistamine, skeletal muscle relaxants, antipsychotic, tricyclic antidepressant, along with a number of approved products pending manufacturing site transfer.
 
Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma, Dr. Reddy's Laboratories and Valeant Pharmaceuticals International. Additional information regarding Elite’s wholly owned products, partnerships, and contract manufacturing can be found at  http://www.elitepharma.com/







\The list of pipeline products can be found at http://www.elitepharma.com/pipeline-generics
 
Leadership
 
Nasrat Hakim, Chairman, President & Chief Executive Officer
 
Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership.  Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company. 

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.
 

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222
Email: 
dianne@elitepharma.com

Corporate Headquarters
165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755


 

Miscellaneous Links:
 
Elite Pharmaceuticals News
http://ir.elitepharma.com/press_releases
 
SEC Filings
http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001053369&owner=include

FDA website
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails

Clinical Trials.Gov
https://www.clinicaltrials.gov/

https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
 
Yahoo Finance
https://finance.yahoo.com/quote/ELTP/?p=ELTP
 
Seeking Alpha
https://seekingalpha.com/symbol/ELTP
 

ELTP Daily Chart:
    


ELTP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ELTP News: Current Report Filing (8-k) 11/16/2020 04:41:44 PM
ELTP News: Quarterly Report (10-q) 11/16/2020 04:05:06 PM
ELTP News: Amended Statement of Beneficial Ownership (sc 13d/a) 09/01/2020 04:04:56 PM
ELTP News: Current Report Filing (8-k) 08/27/2020 05:25:08 PM
ELTP News: Statement of Changes in Beneficial Ownership (4) 08/24/2020 02:19:31 PM
PostSubject
#340817  Sticky Note Watch for a GameChanger ! NASDAQ2020 08/07/20 10:18:53 PM
#339133  Sticky Note Exactly what would you have had him do WeeZuhl 07/21/20 07:39:27 AM
#338107  Sticky Note Shares Outstanding: Makai63 07/10/20 04:36:56 PM
#274770  Sticky Note memorable "calls" for elite pharma: dr_lowenstein 10/24/17 04:09:11 PM
#185967  Sticky Note The only topic here is ELTP. IH Dan (Retired) 02/23/16 09:32:46 PM
#347648   No not really . It is the quality dr_lowenstein 11/28/20 01:46:31 AM
#347647   Utter Nonsense, Accounting 302 It Is Profit!! $2.48-Million JustGoDeep 11/27/20 10:34:15 PM
#347646   Elite always seems to pick the best partners. https://www.codyenterprise.com/ne jour_trader 11/27/20 09:07:42 PM
#347645   Not real profit almost half just accounting profit dr_lowenstein 11/27/20 08:53:21 PM
#347644   Not if you bought at .05 kennyt 335 11/27/20 08:29:23 PM
#347643   Nah, Dramatically Oversold, Thinking Market Maker Shorts Covered!! JustGoDeep 11/27/20 08:28:51 PM
#347642   5 cents = total disaster namtae 11/27/20 08:17:10 PM
#347641   Dramatically Oversold!! $2.48 Million Profit Last Quarter!! JustGoDeep 11/27/20 08:12:24 PM
#347640   another unimpressive day for Unelite. The leak continues. jbdiver 11/27/20 07:16:32 PM
#347638   Market-Makers Working Elite Over With A Rubber Hose!! JustGoDeep 11/27/20 04:08:23 PM
#347637   Welcome to the relatively low prices. Better get Dubster watching 11/27/20 03:42:40 PM
#347636   One billion share That’s Je3232 11/27/20 03:24:37 PM
#347635   The CEO could do many thing to aid namtae 11/27/20 12:48:47 PM
#347634   Why would she do that? Been her meal dr_lowenstein 11/27/20 12:40:24 PM
#347633   Diane reads this site- Je3232 11/27/20 12:20:35 PM
#347632   Another unimpressive day from unelite. The leak continues. jbdiver 11/27/20 11:44:02 AM
#347631   Nasrat Je3232 11/27/20 10:54:24 AM
#347630   Now down 9 percent on 1/2 million shares Je3232 11/27/20 10:26:15 AM
#347629   Stocks go up when there’s a buyathon. Je3232 11/27/20 10:19:10 AM
#347628   Insiders are taking shares Je3232 11/27/20 10:18:15 AM
#347627   Elite will be Undeniable NASDAQ2020 11/27/20 10:08:01 AM
#347626   Insiders accumulating shares. NASDAQ2020 11/27/20 10:06:48 AM
#347625   Wonder if the LPC 03 floor is prophetic. namtae 11/27/20 09:56:36 AM
#347624   Board of Directors Je3232 11/27/20 09:56:26 AM
#347623   Nasrat - down 7.5 percent this morning on Je3232 11/27/20 09:48:24 AM
#347622   Nasrat - Why not return 400,000,000 Je3232 11/27/20 09:34:53 AM
#347621   In my opinion, he ends up with 800,000,000 Je3232 11/27/20 09:31:30 AM
#347620   No doubt in my mind that he will IB_ 11/27/20 09:03:08 AM
#347619  Restored The more shares Nasrat accumulates, the less he IB_ 11/27/20 08:56:33 AM
#347618   My apologies - Nasrat now has 267,272.781 shares. Je3232 11/27/20 08:34:30 AM
#347617   Also,- keep hearing about until there’s a buyout Je3232 11/27/20 08:04:22 AM
#347614   Everything mentioned is great but it’s not showing Je3232 11/27/20 07:25:08 AM
#347613   The bid is 4 1/2 cents Je3232 11/27/20 07:22:36 AM
#347612   five cents per share Je3232 11/26/20 11:07:25 PM
#347611   1500% ROI 6 years ago. NASDAQ2020 11/26/20 10:42:31 PM
#347610   LOL LOL YJ4LIFE 11/26/20 09:31:33 PM
#347608   Early Retirement buyout NASDAQ2020 11/26/20 09:02:25 PM
#347607   Maybe but savvy investors disregard it dr_lowenstein 11/26/20 08:08:27 PM
#347606   If we factor in non recurring revenues for edzett 11/26/20 08:03:43 PM
#347605   What about the pPS Je3232 11/26/20 07:56:18 PM
#347604   In ELTP's Case There-Are-Many-YEARS Of Non-Reoccurring Revenue-Yet-To-Come JustGoDeep 11/26/20 07:55:31 PM
#347603   Nonsense non recurring means it does not recur regularly dr_lowenstein 11/26/20 07:51:36 PM
#347602   "Non Reoccurring" Is Going To Be Reoccurring Well-Into-The-Future!! JustGoDeep 11/26/20 06:41:32 PM
#347601   no it is not, non recurring would not dr_lowenstein 11/26/20 06:22:07 PM
#347600   Number Is Correct, Profit Is Profit!! JustGoDeep 11/26/20 06:12:25 PM
#347599   nope, as much of the so called profit dr_lowenstein 11/26/20 05:48:26 PM
#347598   That would be nice Je3232 11/26/20 05:46:39 PM
#347597   Annualized Profit Now $10 Million And Growing!! JustGoDeep 11/26/20 05:28:26 PM
#347596   Meanwhile ELLTP First Two Profitable Quarters!! JustGoDeep 11/26/20 05:27:44 PM
#347595   Because Elites Board of Directors are not doing IB_ 11/26/20 04:52:35 PM
PostSubject
Consent Preferences